NCT04354103

Atomoxetine in Patients With Tourette's Syndrome

A Pilot Study to Evaluate the Effects of Atomoxetine on Impulsivity in Patients With Tourette's Syndrome

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Poitiers University Hospital · Academic / Other
• Sex: All
• Age: 10 Years – 35 Years
• Healthy volunteers: Accepted

Summary

The purpose of this pilot study is to evaluate the effects of Atomoxetine, a selective noradrenaline reuptake inhibitor, on impulsivity in patients with Tourette's syndrome.

Detailed description

High impulsivity characterizes severe forms of Tourette's syndrome, in which motor and vocal tics are associated with various neuropsychiatric disorders as compulsive disorders, difficult to manage and impairing quality of life of patients and their family. Previous preclinical study and clinical studies in attention-deficit hyperactivity disorder and Parkinson's disease demonstrate that atomoxetine, a selective noradrenaline reuptake inhibitor, improves response inhibition in high impulsive individuals. However, there is no suffisant data in Tourette's syndrome. The purpose of this pilot study is to evaluate the effects of Atomoxetine on impulsivity in 10 to 35 years old patients with Tourette's syndrome.

Conditions

• Tourette Syndrome

Interventions

Type	Name	Description
DRUG	Atomoxetine	Atomoxetine

Timeline

• Start date: 2022-05-31
• Primary completion: 2024-01-19
• Completion: 2024-01-19
• First posted: 2020-04-21
• Last updated: 2024-01-23

Locations

3 sites across 1 country: France